Pollens - grasses, bluegrass, kentucky (june) poa pratensis - Biologic Drug Details

Summary for pollens - grasses, bluegrass, kentucky (june) poa pratensis

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - grasses, bluegrass, kentucky (june) poa pratensis

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract Non-Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - grasses, bluegrass, kentucky (june) poa pratensis Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - grasses, bluegrass, kentucky (june) poa pratensis Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - grasses, bluegrass, kentucky (june) poa pratensis Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Pollen-Based Biologics: Grasses, Bluegrass, Kentucky Bluegrass (June) Poa pratensis

Last updated: February 19, 2026

What are the current developmental and commercial pathways for grass-derived pollen biologics?

Grass pollens, including bluegrass (Poa pratensis), are emerging as a basis for allergen immunotherapy (AIT). The market for allergy biologics targeting grass pollen allergies is expanding, driven by increased prevalence of allergic rhinitis and other respiratory conditions. These biologics either exist as extracts or are under development as standardized, possibly recombinant, formulations.

Market Size and Growth Projections (2023–2030)

• The global allergy immunotherapy market was valued at approximately $5.7 billion in 2022 (Grand View Research, 2023).
• Grass pollen allergen segment accounts for 40% of total allergy immunotherapy revenue, primarily driven by the North American and European markets.
• Compound annual growth rate (CAGR) from 2023 to 2030 estimated at 6.2%, according to MarketWatch (2023).

Key Drivers

• Rising prevalence of allergic rhinitis, affecting 20-30% of adults in developed countries (World Allergy Organization, 2021).
• Increased focus on standardized allergen formulations, reducing adverse effects and improving efficacy.
• Advances in recombinant DNA technology facilitating the development of hypoallergenic, standardized extracts from Poa pratensis and other grasses.

Regulatory Landscape

• The U.S. Food and Drug Administration (FDA) approved Grastek (timothy grass pollen extract) and Oralair (multiple grass pollens) as sublingual immunotherapy (SLIT) products.
• The European Medicines Agency (EMA) approved several grass pollen SLIT tablets, including Grazax.

Production and Supply Chain Challenges

• Standardization of natural grass pollens poses challenges due to geographic and environmental variability.
• Advanced manufacturing techniques, such as recombinant allergen production, seek to address these limitations.

What is the financial trajectory of biotech companies developing Poa pratensis-based biologics?

Leading Companies and Pipeline Status

Company	Product Name	Development Stage	Key Focus
Stallergenes Greer	Oralair	Approved	Multi-grass SLIT tablet
Merck (formerly Genentech)	Recombinant Poa pratensis	Phase 2	Recombinant grass pollen allergen

Investment Trends

• Biotech investments in allergen immunotherapy have grown annually, reaching $1.2 billion in 2022.
• Major venture capital and pharmaceutical companies are investing in recombinant grass pollen technology, aiming for enhanced safety profiles and personalized therapies.

Revenue Projections

• Top-selling grass pollen AIT products generate $300 million to $500 million annually.
• Market penetration is projected to increase as formulations become more standardized and accessible, with potential revenue growth of 8–10% annually over the next decade.

Cost and Pricing Dynamics

• Current SLIT (sublingual immunotherapy) formulations are priced between $600 and $1,200 per year in the U.S.
• Transition to recombinant, hypoallergenic, and standardized products could reduce manufacturing costs by 15–20% and enable price reductions, expanding access.

How do environmental factors influence market and financial outcomes?

• Climate change extends pollen seasons and increases pollen load, amplifying demand for effective immunotherapies.
• Geographic variability influences allergen profiles, with June identified as peak Poa pratensis pollen season in Kentucky and surrounding regions.
• Supply chain disruptions, such as those experienced during the COVID-19 pandemic, sporadically affected raw material supply and manufacturing capacities.

What are the primary challenges and opportunities?

Challenges

• Variability in natural pollen extracts hampers consistent dosing and efficacy.
• Regulatory hurdles for recombinant products with novel formulations.
• Competition from symptomatic treatments like antihistamines and corticosteroids.

Opportunities

• Development of recombinant Poa pratensis allergen formulations offering higher safety and efficacy.
• Expansion into markets with high pollen seasons and allergic disease prevalence.
• Integration of digital tools and personalized medicine to optimize treatment regimens.

Key Financial Takeaways

• The grass pollen allergen immunotherapy market is set for steady growth, driven by technological advances and expanding allergy prevalence.
• Investment in recombinant Poa pratensis biologics offers potential for high margins, subject to regulatory approval.
• Standardization and manufacturing optimization can lower costs, influencing product pricing and accessibility.
• Geographic and environmental factors significantly shape regional market dynamics and supply chain strategies.

---

What are the regulatory considerations for Poa pratensis biologics targeting June pollen seasons in Kentucky?

• Regulatory approval depends on demonstrating consistent allergenic potency, safety, and efficacy.
• The FDA generally requires Phase 1-3 clinical trials for new recombinant products, with similar EMA protocols.
• Timing of production and delivery aligns with pollen seasons; June is critical in Kentucky, requiring synchronized manufacturing schedules.
• Labeling and marketing claims must include region-specific pollen data and seasonal timing.

How does regional pollen seasonality impact market timing and sales?

• Regions like Kentucky experience peak Poa pratensis pollen in June, prompting targeted product launches and marketing campaigns.
• Sales cycles align with pollen seasons, with peak sales occurring shortly before and during peak pollen periods.
• Variability in season timing due to climate change necessitates flexible manufacturing and distribution strategies.

What technological innovations are influencing product development?

• Recombinant DNA techniques create standardized allergen proteins, reducing variability.
• Nanoparticle delivery systems improve allergen stability and immune response modulation.
• Digital bioinformatics facilitates allergen epitope mapping for highly targeted therapies.

What investment risks are associated with Poa pratensis biologics?

• Regulatory delays or denials specific to recombinant products.
• Environmental variables impacting pollen load unpredictability.
• Market penetration challenges from established therapies and generics.

How is market access evolving in emerging economies?

• Regulatory pathways are adapting to recombinant and standardized allergen products.
• Cost reductions from biosimilar developments and manufacturing efficiencies enable broader access.
• Local pollen season data guide tailored product offerings in diverse climatic zones.

---

Key Takeaways

• The global allergy immunotherapy market is expanding with a focus on grass pollen biologics derived from Poa pratensis.
• Investments in recombinant allergen technologies anticipate higher safety profiles and market differentiation.
• Regional seasonality, especially June in Kentucky, influences product launch timing and sales strategies.
• Regulatory frameworks favor standardized, recombinant products, but adherence and approval timelines vary.
• Environmental factors and climate change influence pollen seasons, impacting both supply and demand.

FAQs

1. What makes Poa pratensis a focus for biologic development?
   Its prevalence in North American lawns and pastures makes it a significant allergen source during peak pollen seasons. Standardized recombinant forms offer potential for consistent, safe immunotherapy.

2. When do Poa pratensis pollen seasons occur in Kentucky?
   Peak in June; variability exists depending on climate conditions. This impacts timing for treatment administration and market activity.

3. Are recombinant grass pollen biologics approved for general use?
   Some are approved, such as Oralair in the U.S. and Europe, but ongoing development aims to improve safety and efficacy further. Many products remain under clinical evaluation.

4. How will climate change affect market projections?
   Longer and more intense pollen seasons could increase demand, but climate variability may complicate supply chains and seasonal targeting.

5. What are the main competing therapies?
   Symptomatic allergy medications like antihistamines and corticosteroids; traditional grass pollen immunotherapy also competes with emerging recombinant biologics.

---

References

1. Grand View Research. (2023). Allergy Immunotherapy Market Size, Share & Trends Analysis Report.
2. MarketWatch. (2023). Allergy Immunotherapy Market Size, Growth & Forecast.
3. World Allergy Organization. (2021). Epidemiology of Allergic Rhinitis.